• GIP/GLP-1 dual agonist benefits type 2 diabetes patients with heart disease
• Met primary non-inferiority endpoint vs. Trulicity with 8% fewer MACE-3 events
• Delivered greater reductions in A1C and weight
• Reinforces Mounjaro’s strong CV and metabolic profile
• Peers mentioned: $NVO (-2,26 %)
$VKTX (+0,45 %)